Structure-activity relationship study of dihydroartemisinin C-10 hemiacetal derivatives as Toll-like receptor 4 antagonists

2021 ◽  
pp. 105107
Author(s):  
Shuo Wang ◽  
Hongshuang Wang ◽  
Cong Lin ◽  
Tianshu Zhang ◽  
Jingwei Gao ◽  
...  
Keyword(s):  
Structure Activity Relationship ◽  
Activity Relationship ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Structure Activity ◽  
Relationship Study

scholarly journals Structure-Activity Relationship of Synthetic Toll-like Receptor 4 Agonists

2003 ◽  
Vol 279 (6) ◽  
pp. 4440-4449 ◽  
Author(s):  
Axel G. Stöver ◽  
Jean Da Silva Correia ◽  
Jay T. Evans ◽  
Christopher W. Cluff ◽  
Mark W. Elliott ◽  
...  
Keyword(s):  
Structure Activity Relationship ◽  
Activity Relationship ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Structure Activity ◽  
Relationship Of

scholarly journals Structure–Activity Relationship in Monosaccharide-Based Toll-Like Receptor 4 (TLR4) Antagonists

2018 ◽  
Vol 61 (7) ◽  
pp. 2895-2909 ◽  
Author(s):  
Fabio A. Facchini ◽  
Lenny Zaffaroni ◽  
Alberto Minotti ◽  
Silvia Rapisarda ◽  
Valentina Calabrese ◽  
...  
Keyword(s):  
Structure Activity Relationship ◽  
Activity Relationship ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Structure Activity

scholarly journals Structure–Activity Relationship Studies of Pyrimido[5,4-b]indoles as Selective Toll-Like Receptor 4 Ligands

2017 ◽  
Vol 60 (22) ◽  
pp. 9142-9161 ◽  
Author(s):  
Michael Chan ◽  
Yuhei Kakitsubata ◽  
Tomoko Hayashi ◽  
Alast Ahmadi ◽  
Shiyin Yao ◽  
...  
Keyword(s):  
Structure Activity Relationship ◽  
Activity Relationship ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Structure Activity

Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles

2021 ◽  
Author(s):  
Deepender Kaushik ◽  
Arshpreet Kaur ◽  
Nikolai Petrovsky ◽  
Deepak B. Salunke
Keyword(s):  
Structural Evolution ◽  
Structure Activity Relationship ◽  
Activity Relationship ◽  
Vaccine Adjuvant ◽  
Toll Like Receptor ◽  
Detailed Structure ◽  
Structure Activity

TLR7/8 agonists are emerging as promising vaccine adjuvant candidates. An evolution of imidazole based TLR7/8 agonist from imidazoquinoline based scaffold is delineated along with the elaboration of detailed structure activity relationship (SAR) in each chemotype.

Sign in / Sign up

Export Citation Format

Share Document